Mark L. Pearson, Ph.D.

Mark L. Pearson, Ph.D. is a Co-Founder and Director of TheoremDx (n/c. formerly Ovagene Oncology) since 2017. Prior to this, they were a Co-Founder and Board Member of OvaGene Oncology since 2009, and a Retired Biotechnology Executive since 2010. From 2007 to 2009, they were the Managing Partner of Thompson River Capital LLC, a privately held equity management firm dedicated to the healthcare industry. From 2006 to 2007, they were the CEO and Director of NeuroMedix Inc., a biopharmaceutical company. From 2005 to 2006, they were the CEO and Director of Protana Inc., a company providing an integrated platform of sensitive technologies for drug discovery and development process. From 2002 to 2005, they were the Vice President of Corporate Development & Strategy at MDS Inc. From 1999 to 2002, they were the Senior Vice President of MDS Proteomics Inc. and from 1994 to 1999, they were the President of Molecumetics Inc.

Mark L. Pearson, Ph.D. began their education in 1958 at the University of Toronto, where they earned a B.A.Sc. in Engineering Physics. Mark L. then continued their studies at the same institution, receiving a Master's Degree in Medical Biophysics in 1964. This was followed by a Ph.D. in Medical Biophysics from the University of Toronto in 1966. Mark L. then went on to Stanford University School of Medicine, where they completed a Post-doc in Biochemistry from 1966 to 1969. In 1977, they took a sabbatical from Stanford University to do research in DNA sequencing. In 1990, they attended Columbia University's Graduate School of Business. Finally, in 1992, they completed a Program for Advanced Training in Biomedical Research Management at the Harvard T.H. Chan School of Public Health.